187 related articles for article (PubMed ID: 27648357)
1. EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells.
Hsieh YY; Lo HL; Yang PM
Am J Cancer Res; 2016; 6(8):1661-80. PubMed ID: 27648357
[TBL] [Abstract][Full Text] [Related]
2. [Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].
Xiao LR; Hou C; Zheng SJ; Guo B; Chen DN; Yan NH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):305-310. PubMed ID: 31631594
[TBL] [Abstract][Full Text] [Related]
3. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
4. p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
Yang PM; Hong YH; Hsu KC; Liu TP
Am J Cancer Res; 2019; 9(10):2120-2139. PubMed ID: 31720078
[TBL] [Abstract][Full Text] [Related]
5. In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.
Liu TP; Hong YH; Tung KY; Yang PM
Oncoscience; 2016; 3(1):9-20. PubMed ID: 26973856
[TBL] [Abstract][Full Text] [Related]
6. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
7. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
8. GSK343 induces autophagy and downregulates the AKT/mTOR signaling pathway in pancreatic cancer cells.
Xu H; Zhang L; Qian X; Zhou X; Yan Y; Zhou J; Ge W; Albahde M; Wang W
Exp Ther Med; 2019 Oct; 18(4):2608-2616. PubMed ID: 31572509
[TBL] [Abstract][Full Text] [Related]
9. GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.
Xiong X; Zhang J; Li A; Dai L; Qin S; Wang P; Liu W; Zhang Z; Li X; Liu Z
Cancer Biol Ther; 2020; 21(3):213-222. PubMed ID: 31651209
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
11. EZH2 inhibitor GSK343 inhibits sepsis-induced intestinal disorders.
Yue D; Wang Z; Yang Y; Hu Z; Luo G; Wang F
Exp Ther Med; 2021 May; 21(5):437. PubMed ID: 33747174
[TBL] [Abstract][Full Text] [Related]
12. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
13. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
Yu T; Wang Y; Hu Q; Wu W; Wu Y; Wei W; Han D; You Y; Lin N; Liu N
Oncotarget; 2017 Nov; 8(58):98348-98359. PubMed ID: 29228694
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.
Pereira ASA; Amaral MS; Vasconcelos EJR; Pires DS; Asif H; daSilva LF; Morales-Vicente DA; Carneiro VC; Angeli CB; Palmisano G; Fantappie MR; Pierce RJ; Setubal JC; Verjovski-Almeida S
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006873. PubMed ID: 30365505
[TBL] [Abstract][Full Text] [Related]
15. GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-κB/IκBα Pathways.
Scuderi SA; Filippone A; Basilotta R; Mannino D; Casili G; Capra AP; Chisari G; Colarossi L; Sava S; Campolo M; Esposito E; Paterniti I
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430394
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells.
Yao Y; Hu H; Yang Y; Zhou G; Shang Z; Yang X; Sun K; Zhan S; Yu Z; Li P; Pan G; Sun L; Zhu X; He S
Genes (Basel); 2016 Oct; 7(10):. PubMed ID: 27706111
[TBL] [Abstract][Full Text] [Related]
17. ATG5 and ATG7 induced autophagy interplays with UPR via PERK signaling.
Zheng W; Xie W; Yin D; Luo R; Liu M; Guo F
Cell Commun Signal; 2019 May; 17(1):42. PubMed ID: 31060556
[TBL] [Abstract][Full Text] [Related]
18. Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy.
Papandreou I; Verras M; McNeil B; Koong AC; Denko NC
Exp Cell Res; 2015 Nov; 339(1):147-53. PubMed ID: 26477823
[TBL] [Abstract][Full Text] [Related]
19. EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells.
Zhang X; Ma X; Wang Q; Kong Z
Transl Oncol; 2022 Feb; 16():101316. PubMed ID: 34952334
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway.
Chen Z; Du Y; Liu X; Chen H; Weng X; Guo J; Wang M; Wang X; Wang L
Oncol Lett; 2019 Jul; 18(1):907-915. PubMed ID: 31289569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
